ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.
"We believe the therapies Novartis is developing with our ADC technology have the potential to make an important difference for patients," commented Daniel Junius, President and CEO.
This is the second license to be taken by Novartis under a 2010 agreement between the companies. For each license, ImmunoGen receives an upfront payment and is entitled to receive milestone payments potentially totaling approximately $200 million plus royalties on the sales of any resulting products. Novartis is responsible for the development, manufacturing and marketing of any products resulting from the license.
The World Vaccine Congress heads to Amsterdam, where it will draw experts and leaders from science, academia, start-ups, biotechnology and pharmaceutical companies making this event Europe’s most attractive R&D conference